Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00225251
Status:
COMPLETED
Last Update Posted:
2015-11-26
First Post:
2005-09-21
Brief Title:
Wellbutrin XL for Dysthymic Disorder
Sponsor:
St Lukes-Roosevelt Hospital Center
Organization:
St Lukes-Roosevelt Hospital Center
Study Overview
Official Title:
Double-Blind Treatment of Outpatients With Dysthymic Disorder With Wellbutrin XL
Status:
COMPLETED
Status Verified Date:
2014-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a ten-week double-blind study of Wellbutrin XL in outpatients with dysthymic disorder a form of low-grade chronic depression We hypothesize that patients taking Wellbutrin XL will show greater improvement in depression symptoms and psychosocial functioning than patients taking placebo
Detailed Description:
This is a ten-week double-blind placebo-controlled study designed to evaluate the tolerability dosing and efficacy of Wellbutrin XL in outpatients who meet Diagnostic and Statistical Manual-IV criteria for early onset primary type dysthymic disorder low-grade chronic depression It is hypothesized that patients taking Wellbutrin XL will show greater improvement in depression symptoms and psychosocial functioning than patients taking placebo
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None